V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 310004343 | 310011079 | 1.68 | 75 | Palliative (P) | 2013-12-25 | 2013-12-25 | Hydroxycarbamide | 2 | N | 310019677 | GEMCITABINE + PACLITAXEL |
| 310004344 | 310010403 | 1.66 | 74.7 | Adjuvant (A) | 2017-04-24 | 2017-04-24 | Gemcitabine 1000mg/m2 D1 8 15 | null | null | 310019679 | GEMCITABINE |
| 310004345 | 310001885 | null | 84.7 | Adjuvant (A) | 2017-04-24 | 2017-04-25 | ECX | N | N | 310019680 | ECX |
| 310004346 | 310001885 | null | 0 | Neo-adjuvant (N) | 2016-07-25 | 2016-07-30 | BEVACIZUMAB + CARBO + PACLITAXEL | N | N | 310019680 | BEVACIZUMAB + CARBO + PACLITAXEL |
| 310004348 | 310006808 | 0 | null | Adjuvant (A) | 2014-01-22 | 2014-01-22 | Gemcitabine weekly | N | null | 310019683 | GEMCITABINE |
| 310004351 | 310001888 | 1.6 | 80.3 | Neo-adjuvant (N) | 2015-01-26 | 2015-02-07 | Dacarbazine | N | N | 310019687 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 310004353 | 310001889 | 1.84 | 69.7 | Adjuvant (A) | 2017-04-08 | 2017-04-29 | EOX | null | null | 310019689 | HYDROXYCARBAMIDE |
| 310004354 | 310001890 | 1.73 | 79 | null | 2014-11-19 | 2014-11-19 | CHOEP - 21 days | N | N | 310019692 | CHOEP |
| 310004355 | 310006811 | 1.64 | null | Palliative (P) | 2015-01-14 | 2015-01-18 | EOX | 02 | N | 310019693 | DACARBAZINE |
| 310004356 | 310006811 | null | null | Curative (C) | 2015-11-22 | 2015-11-24 | STS Rhabdomyosarcoma RMS 2005 IVAVV | 02 | N | 310019693 | NOT MATCHED |
| 310004358 | 310001892 | null | null | null | 2013-12-29 | 2013-12-30 | Hydroxycarbamide | 02 | null | 310019697 | RITUXIMAB |
| 310004359 | 310001892 | 1.61 | 79 | null | null | 2013-05-05 | CHOEP - 21 days | N | N | 310019697 | PACLITAXEL |
| 310004360 | 310001893 | 0 | 0 | null | 2013-09-04 | 2013-09-22 | EOX | 2 | N | 310019702 | VEMURAFENIB |
| 310004361 | 310001894 | 1.66 | null | Palliative (P) | 2013-12-17 | 2014-01-06 | Cisplatin +Fluorouracil (2 wk) | N | N | 310019710 | OXALIPLATIN + MDG |
| 310004362 | 310006813 | null | null | Adjuvant (A) | 2017-06-28 | 2017-07-06 | Rituximab | null | N | 310019712 | GEMCITABINE + PACLITAXEL |
| 310004363 | 310001895 | 1.68 | null | Palliative (P) | 2016-10-08 | 2016-10-22 | Dacarbazine | 2 | N | 310019713 | OXALIPLATIN + MDG |
| 310004364 | 310001896 | 0 | 51.8 | Palliative (P) | 2015-11-22 | 2015-11-23 | Vemurafenib | N | N | 310019714 | GEMCITABINE + PACLITAXEL |
| 310004365 | 310001897 | 1.7 | 80.2 | Neo-adjuvant (N) | 2013-11-14 | 2013-11-16 | BEVACIZUMAB + CARBO + PACLITAXEL | N | null | 310019716 | BEVACIZUMAB + CARBO + PACLITAXEL |
| 310004366 | 310001898 | 1.78 | 72 | Neo-adjuvant (N) | 2017-11-30 | 2017-11-30 | Dacarbazine | 02 | N | 310019717 | RITUXIMAB |
| 310004367 | 310001898 | null | 54.4 | Neo-adjuvant (N) | 2013-10-23 | 2013-10-24 | Oxaliplatin + Modified de Gramont | N | N | 310019717 | CAPECITABINE + CISPLATIN |
| 310004368 | 310001899 | 1.46 | 73.2 | Disease modification (D) | 2013-01-17 | 2014-02-27 | GEM-P | 2 | N | 310019720 | LIPOSOMAL DOXORUBICIN |
| 310004369 | 310001899 | 1.91 | null | Curative (C) | 2017-04-12 | 2017-04-18 | Capecitabine + Cisplatin | 02 | N | 310019720 | ICON TRIAL |
| 310004370 | 310001899 | 1.46 | 72.1 | Palliative (P) | 2014-09-11 | 2014-09-26 | ECX | N | N | 310019720 | ECX |
| 310004371 | 310001900 | 1.9 | 58.8 | Adjuvant (A) | 2013-09-13 | 2013-09-13 | CHOEP - 21 days | 02 | N | 310019724 | CHOEP |
| 310004372 | 310001901 | 1.68 | 58 | Palliative (P) | null | 2015-07-06 | IPILIMUMAB + NIVOLUMAB | N | N | 310019726 | IPILIMUMAB + NIVOLUMAB |
| 310004373 | 310001902 | null | 97 | Palliative (P) | 2013-08-15 | 2013-09-02 | ICON8 TRIAL | N | null | 310019727 | OXALIPLATIN + MDG |
| 310004374 | 310001902 | null | null | Palliative (P) | 2017-11-29 | 2017-12-12 | IPILIMUMAB + NIVOLUMAB | 2 | N | 310019727 | IPILIMUMAB + NIVOLUMAB |
| 310004376 | 310001904 | 1.66 | 67.7 | Palliative (P) | 2017-03-12 | 2017-03-18 | Hydroxycarbamide | null | null | 310019734 | VEMURAFENIB |
| 310004377 | 310006817 | 0 | 0 | Disease modification (D) | 2016-06-24 | 2016-06-24 | Hydroxycarbamide | N | N | 310019735 | CISPLATIN + FLUOROURACIL |
| 310004378 | 310006817 | 1.71 | 102.2 | Palliative (P) | 2014-03-21 | 2014-04-18 | IPILIMUMAB + NIVOLUMAB | 02 | N | 310019735 | IPILIMUMAB + NIVOLUMAB |
| 310004379 | 310001905 | 1.73 | 73.4 | Curative (C) | 2016-08-04 | 2016-08-14 | ECX | 02 | N | 310019738 | MITOMYCIN INTRAVESICULAR |
| 310004380 | 310001906 | 0 | 94.2 | null | null | 2015-08-08 | GEMCITABINE | 2 | N | 310019739 | GEMCITABINE |
| 310004381 | 310006818 | 1.67 | 113.8 | Disease modification (D) | 2017-02-10 | 2017-02-14 | EOX | N | N | 310019742 | LIPOSOMAL DOXORUBICIN |
| 310004382 | 310001907 | 0 | 77.5 | Curative (C) | 2015-07-13 | 2015-07-13 | IPILIMUMAB + NIVOLUMAB | 2 | N | 310019744 | PACLITAXEL |
| 310004384 | 310001909 | 1.7 | null | null | null | 2016-02-10 | Vemurafenib | N | N | 310019749 | ICON TRIAL |
| 310004385 | 310001910 | 0 | 58 | Adjuvant (A) | 2013-05-09 | 2013-05-18 | CISPLATIN + FLUOROURACIL | N | N | 310019750 | CAPECITABINE + CISPLATIN |
| 310004387 | 310001912 | 1.73 | null | Disease modification (D) | 2015-08-12 | 2015-08-13 | CISPLATIN + DOCETAXEL + FLUOROURACIL | null | null | 310019753 | VEMURAFENIB |
| 310004388 | 310001913 | 1.67 | 78.9 | Palliative (P) | 2017-04-19 | 2017-11-27 | CISPLATIN + DOCETAXEL + FLUOROURACIL | 02 | Y | 310019754 | GEMCITABINE + PACLITAXEL |
| 310004389 | 310001914 | null | 56.7 | Neo-adjuvant (N) | 2017-10-17 | 2017-12-07 | Dacarbazine | 2 | N | 310019756 | OXALIPLATIN + MDG |
| 310004390 | 310001914 | null | 97.6 | null | 2018-05-07 | 2018-05-09 | Capecitabine + Cisplatin | N | N | 310019756 | LIPOSOMAL DOXORUBICIN |
| 310004391 | 310001915 | null | null | Palliative (P) | 2013-02-26 | 2013-03-27 | Bexarotene | N | null | 310019761 | EOX |
| 310004392 | 310001915 | 1.68 | 109.4 | Palliative (P) | 2014-10-30 | 2014-11-13 | EOX | N | N | 310019761 | CISPLATIN + FLUOROURACIL |
| 310004393 | 310009172 | 1.86 | 0 | Palliative (P) | null | 2016-01-30 | IPILIMUMAB + NIVOLUMAB | N | N | 310019766 | IPILIMUMAB + NIVOLUMAB |
| 310004394 | 310009172 | 1.8 | 79 | Neo-adjuvant (N) | null | 2016-05-30 | BEVACIZUMAB + CARBO + PACLITAXEL | N | N | 310019766 | BEVACIZUMAB + CARBO + PACLITAXEL |
| 310004395 | 310001916 | 1.72 | 64 | Curative (C) | 2017-10-27 | 2017-11-16 | Oxaliplatin + Modified de Gramont | N | N | 310019769 | IMATINIB |
| 310004396 | 310001916 | 1.57 | 76.1 | Palliative (P) | 2016-01-25 | 2016-02-18 | IPILIMUMAB + NIVOLUMAB | 2 | N | 310019769 | IPILIMUMAB + NIVOLUMAB |
| 310004397 | 310001917 | 1.71 | 72 | null | 2017-08-20 | 2017-08-26 | NB HRNBL-1 COJEC Ind COURSE A | N | null | 310019771 | NOT MATCHED |
| 310004398 | 310001918 | 1.66 | 65 | Palliative (P) | 2016-09-30 | 2016-10-23 | Gemcitabine day 1&8 | N | N | 310019772 | PACLITAXEL |
| 310004399 | 310001919 | 1.52 | 71 | Palliative (P) | 2016-04-30 | 2016-05-10 | Bexarotene | N | N | 310019773 | ICON TRIAL |
| 310004400 | 310001920 | null | null | Adjuvant (A) | 2017-12-08 | 2017-12-08 | CISPLATIN + FLUOROURACIL | null | null | 310019774 | OXALIPLATIN + MDG |